AKT1 and lung carcinoma: The downregulation of p-Akt and p-STAT3 suggests that the combination treatment interferes with these signaling pathways, potentially influencing downstream targets such as SLC7A11 and inducing ferroptosis in lung cancer cells (Zhao et al., 2019; Wang J-G.